These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 27792012)

  • 1. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
    JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort.
    Amft M; Ortner M; Eichenlaub U; Goldhardt O; Diehl-Schmid J; Hedderich DM; Yakushev I; Grimmer T
    Alzheimers Res Ther; 2022 Apr; 14(1):60. PubMed ID: 35473631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
    Zwan M; van Harten A; Ossenkoppele R; Bouwman F; Teunissen C; Adriaanse S; Lammertsma A; Scheltens P; van Berckel B; van der Flier W
    J Alzheimers Dis; 2014; 41(3):801-7. PubMed ID: 24705549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences.
    Lombardi G; Pupi A; Bessi V; Polito C; Padiglioni S; Ferrari C; Lucidi G; Berti V; De Cristofaro MT; Piaceri I; Bagnoli S; Nacmias B; Sorbi S
    J Alzheimers Dis; 2020; 77(1):203-217. PubMed ID: 32716357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.
    Adamczuk K; Schaeverbeke J; Vanderstichele HM; Lilja J; Nelissen N; Van Laere K; Dupont P; Hilven K; Poesen K; Vandenberghe R
    Alzheimers Res Ther; 2015 Dec; 7(1):75. PubMed ID: 26677842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
    West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE
    Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.